NCT04715633View on ClinicalTrials.gov

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

August 30, 2023

Study Completion Date

July 31, 2025

Conditions
Colorectal CancerMicrosatellite Instability High
Interventions
DRUG

PD-1 inhibitor plus VEGF inhibitors

Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14. Rescue chemotherapy: Oxaliplatin 130mg/m2 IV drip Q3W d1+Capecitabine 1000mg/m2 QD d1-d14 Rescue chemoradiotherapy: Long-course radiotherapy +Capecitabine 825mg/m2 QD d1-d14

Trial Locations (1)

510060

651 Dongfeng Road East, Guangzhou

All Listed Sponsors
collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

Guangdong Provincial Hospital of Traditional Chinese Medicine

OTHER

lead

Sun Yat-sen University

OTHER